Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.
|Articles|January 1, 1996
Oncology NEWS International
- Oncology NEWS International Vol 5 No 1
- Volume 5
- Issue 1
Zoladex Gets Indication for Advanced Breast Ca
WILMINGTON, Del--Zoladex (goserelin acetate implant), Zeneca Pharmaceuticals' gonadotropin-releasing-hormone (GnRH) agonist, has received approval for use in the treatment of advanced breast cancer in premenopausal and perimenopausal women.
Advertisement
WILMINGTON, Del--Zoladex (goserelin acetate implant), Zeneca Pharmaceuticals'gonadotropin-releasing-hormone (GnRH) agonist, has received approvalfor use in the treatment of advanced breast cancer in premenopausaland perimenopausal women.
The agent was introduced in the United States for the treatmentof advanced prostate cancer in 1989 and for the treatment of endometriosisin 1993.
Zoladex, given by injection once a month, acts on the pituitarygland to cause decreased production of estrogen by the ovaries.This lowers serum estrogen levels to concentrations typical ofpostmenopausal women, reducing estrogen stimulation of breasttumor growth.
The new indication is based on results of clinical trials involvingmore than 800 women in North America and Europe, showing responserates and survival benefits comparable to those achieved by oophorectomy,the company said.
Articles in this issue
almost 31 years ago
HCFA Reevaluations May Affect Chemo Administration Cost Codesalmost 31 years ago
Breast Cancer Info Now on Internetalmost 31 years ago
HDC/ABMT Has Benefits in Multiple Myelomaalmost 31 years ago
Clinical Trial to Study MoAb 17-1A as An Adjuvant to Colon Cancer Therapyalmost 31 years ago
Reporting of Study Comparing Casodex, Eulexin Is Questionedalmost 31 years ago
Limits on Tamoxifen Duration Questionedalmost 31 years ago
ACRO Forecasts Radiologist Surplusalmost 31 years ago
Potency Status Before RT, Not Dose, Determines Post-RT Functionalmost 31 years ago
Dr. Klausner Outlines Goals for NCIalmost 31 years ago
Difficulties in Translating Relative Risks Into Absolute RiskAdvertisement
Related to this article
In HypoMast-IMNI, 16-fraction PMRT with internal mammary node irradiation matched conventional RT for locoregional control with less grade 3 skin toxicity.
Mark Burkard, MD, PhD, discussed genomic gaps, extreme survivors of metastatic breast cancer, and how minimal residual disease testing may refine care.
Hope S. Rugo, MD, discussed KEYNOTE-B49 data showing pembrolizumab plus chemotherapy improved PFS in PD-L1-positive HR+/HER2- breast cancer.
Jan Kitajewski, PhD, discusses how an ancestry-linked blood type may influence triple-negative breast cancer outcomes and clinical trial eligibility.
Black women die from breast cancer at rates 40% higher than white women — and are still missing from the trials that could help. Dr. Coral Omene on why.
The European Commission approved adjuvant T-DXd for HER2-positive early breast cancer with residual invasive disease based on DESTINY-Breast05 data.
Jan Kitajewski, PhD, explains how Notch inhibitors may sustain specialized tumor blood vessels that deliver immune cells and boost immuno-oncology.
Advertisement
Advertisement
Trending on CancerNetwork
1
Pasritamig Plus JNJ-9401 Yields 73% PSA Response in Metastatic CRPC
2
Nogapendekin Alfa/BCG Earns Israeli Approval in BCG-Unresponsive NMIBC
3
PIKTOR Plus Paclitaxel Yields Responses in Pretreated PAM-Mutated Endometrial Cancer
4
Managing Dermatologic Toxicity and Holding Therapy
5